*Sponsored
Jeff Ackerman Initiates Coverage On (INBS) Starting This
Morning—Wednesday, July 16, 2025
(INBS) Comes Backed By Several Potential Catalysts Including:
Recent Analyst Coverage From Ladenburg Thalmann Indicates (INBS) Received A $12 Target, Which Suggests Over 530% Upside Potential.
With Fewer Than 7M Shares In The Float, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Has The Potential To Witness Significant Swings If Demand Begins To Shift.
Fingerprint-Based Screening Devices From (INBS) Are Already In Use Across 450+ Customer Accounts And 1,000+ Active Deployments.
(INBS) Reported A 148% Increase In Annual Revenue And A 32.6% Boost In Gross Pro-fit Alongside A Growing Customer Base.
With FDA 510(k) Clearance Anticipated In The First Half Of 2025, (INBS) Is Preparing For U.S. Launch Later This Year.
Take A Look At (INBS) While It's Still Early…
July 16, 2025 Wednesday's Watchlist | See Why (INBS) Just Hit Our Radar This Morning Dear Reader, Sometimes the most intriguing developments don't start with a bang. No headlines. No social buzz. Just a quiet release from a well-established firm—and a target that practically demands a second look. The name behind it? Still flying under the radar. Still below $2. But maybe not for long. But with a tight float, real-world traction, and a new $12 target from Ladenburg Thalmann—it may not stay quiet for long. That company is Intelligent Bio Solutions Inc. (NASDAQ: INBS)—a sub-$12M profile with fewer than 7M shares in the float and a fingerprint-based screening system already deployed across 450+ customers in 24 countries. And earlier this week, analyst Jeffrey S. Cohen lit it up with a $12 target—which suggests over 530% upside from yesterday's $1.90 close. 
Few Know What This Fingerprint Tech Is Quietly Disrupting
Most still think of dr-ug screening as urine tests, long wait times, and awkward procedures. But one company is changing that—using fingerprint sweat to detect substances like opi-ates, co-cai-ne, and fen-ta-nyl. This isn't theoretical. Over 1,000 devices are already in the field, with U.S. expansion expected later this year. The test takes under 10 minutes using just a fingerprint—and in FDA-submitted data, it delivered 94.1% accuracy and 100% specificity for opi-ates. For employers, it's not just cleaner and faster—it may redefine the standard. Recent Growth Highlights:
- 32.6% YoY gross pro-fit growth (Q4 2024)
- Gross margins up to 38.5%
- 19 new customer accounts last quarter
- Recurring cartridge sales continue to scale under a razor/razor-blade model
- 148% revenue growth YoY (FY ending June 2024)
U.S. Launch Expected Following 510(k) Submission
The company filed its 510(k) submission in December 2024 and anticipates U.S. clearance in the first half of 2025, with a commercial launch planned for the second half—starting with opiate detection and expanding from there. The U.S. workplace is a primary focus.
Substance misuse costs the nation over $400B annually, and more than 70% of those affected are employed. Meanwhile, test positivity rates have risen for five consecutive years. Why Fingerprint Screening?
This approach removes many of the burdens tied to traditional methods: - No gender-specific supervision
- No hazardous waste
- No special training required
- No waiting for a sample
It's clean, fast, and discreet. Some users report it cuts costs by 50%—eliminating both lab fees and employee downtime in the process. Beyond the Fingerprint: INBS Adds Long-Window Detection Patch
Now, the company is expanding its non-invasive platform even further. In July 2025, it introduced the SmarTest® Patch, a wearable device designed for continuous detection of substances like fen-tan-yl, opi-ates, and co-cai-ne via sweat—over a 7 to 10-day period. Developed by SMARTOX®, this tamper-evident patch complements the existing fingerprint system, offering customers a broader range of options for both short- and long-window testing scenarios. From pre-employment screening to justice and rehabilitation settings, the SmarTest Patch adds new flexibility to an already disruptive platform. From Europe to the U.S.—With Data to Back It Up
(INBS) already serves real-world customers across the U.K. and other international markets, including P&O Ferries and industrial service providers. These aren't test pilots—they're live deployments. Recent clinical work supports the company's expansion: - In a PK study, fingerprint sweat tracked closely with codeine levels in blood and saliva.
- In a 135-subject comparison against LC-MS/MS lab methods, the fingerprint system's results matched closely—validating its reliability.
Recent Developments
July 15, 2025 – INBS Launches SmarTest® Patch, a 10-Day Wearable for Dr-ug Detection
(INBS) added the SmarTest® Patch to its product lineup—a discreet, tamper-evident wearable developed by SMARTOX® that detects dr-ugs through sweat for up to 10 days. It complements INBS's flagship fingerprint system and expands reach into justice and rehab markets. [See Full News Release] July 10, 2025 – INBS to Present PK Study at ADLM 2025 in Chicago
(INBS) will share clinical PK data showing strong alignment between fingerprint sweat and traditional blood/saliva dr-ug detection—bolstering credibility for diagnostic use. [See Full News Release] June 25, 2025 – INBS Expands in Scandinavia via Spjotgard Partnership
(INBS) is gaining traction in Sweden, Norway, and Denmark through distributor Spjotgard, with customers across logistics, education, and justice adopting the platform. [See Full News Release] June 18, 2025 – INBS Deploys Fingerprint Testing at 20+ Sites in Australia
(INBS) rolled out its solution at over 20 Managed Waste Service sites in New South Wales, streamlining compliance testing and enabling on-site, real-time results. [See Full News Release] June 11, 2025 – INBS Grows U.S. Forensic Use with SMARTOX Partnership
With over 7,000 tests and 50+ devices deployed via SMARTOX, (INBS) is expanding in U.S. corrections and rehab while pursuing FDA clearance for workplace screening.
[See Full News Release] These developments demonstrate a clear execution path—from technology deployment to global scalability—and position (INBS) for increased visibility and adoption in key international markets. While Others Are Still Testing, (INBS) Has Already Filed With the FDA
(INBS) may still be flying under the radar—but its real-world deployments, accelerating revenue, and active 510(k) submission suggest it's operating on a different level than peers still buried in research and development. With fewer than 7M shares in the float, a recurring-revenue cartridge model, and growing demand for modern workplace screening, this company appears to be on the cusp of something bigger. Fingerprinting has long been tied to identity. Now, it's quietly becoming a fast, accurate window into recent substance exposure—without needles, cups, or lab delays. Whether that transformation redefines the category or simply carves out a dominant niche, one thing is clear: the foundation is already being laid. The tech works. The infrastructure is scaling. And the regulatory wheels are turning. Add in the structural tailwinds—and the signals are hard to ignore. That's why (INBS) is firmly locked on our radar heading into Wednesday morning Here's 7 Reasons Why (INBS) Is Topping Our Watchlist This Morning—Wednesday, July 16, 2025…
1. Low Float: With fewer than 7M shares listed in the float and a market cap under $12M, (INBS) has the kind of structure that has historically witnessed significant swings if demand begins to shift.
2. Analyst Target: Yesterday, July 14, 2025, a senior analyst from one of the country's oldest firms issued a $12 target on (INBS)—which suggests more than 530% upside potential from yesterday's $1.90 close.
3. Real Tech, Already in Use: This isn't a concept-stage company. Its fingerprint-based screening devices are already deployed across 450+ customer accounts—with over 1,000 systems in the field and international users actively relying on the platform. 4. Explosive Revenue Growth: (INBS) reported a 148% jump in annual revenue and a 32.6% increase in gross pro-fit—alongside margin expansion and a growing customer base, all pointing to consistent operational progress. 5. U.S. Launch Pending: (INBS) is preparing for a second-half 2025 rollout following an active FDA 510(k) submission filed in December 2024. 6. Breakthrough Simplicity: Unlike traditional methods that require supervision, lab delays, and biological waste management, (INBS) offers non-invasive fingerprint-based testing with results in under 10 minutes. That kind of simplicity could change expectations for workplace and field-based screening environments. 7. Expanding Global Reach: In just the last few months (INBS) launched multilingual support (Arabic, Spanish, Italian), localized its digital presence, and presented at a key industry conference—reinforcing its focus on real-world visibility and adoption across diverse regions. Potential catalysts are stacking up—and (INBS) could be walking into the spotlight, even as the story remains under the radar for most. Take A Look At (INBS) While It's Still Early…
See (INBS)'s Corporate Presentation Here With real-world adoption already underway, multilingual expansion accelerating, and a float tight enough to catch notice when attention shifts—Intelligent Bio Solutions Inc. (NASDAQ: INBS) is showing signs of a company moving with purpose. Backed by a bold $12 target from a senior analyst, consistent year-over-year growth, and a pending U.S. entry in 2025, the pieces are lining up at a time when most are still catching up to the story. We have (INBS) at the top of our screens this morning. Take a look at (INBS) while it's still early. My next update could be here before the bell rings—keep an eye out for it. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends
| 
Tidak ada komentar:
Posting Komentar